News for Bioventus Inc. (BVS)

Bioventus (BVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Revenue: $154 million in Q4, a 14% increase year-over-year.Organic Revenue Growth: 14% for 2024, with Q4 growth nearly 14%.Surgical Solutions Revenue: Accelera

Mar 11, 2025 / 12:30PM GMTOperator Good morning and welcome to the Bioventus fourth-quarter 2024 earnings conference call. (Operator Instructions) Please note t

Bioventus Inc. (NASDAQ:BVS) Q4 2024 Earnings Conference Call March 11, 2025 8:30 AM ETCompany ParticipantsDave Crawford - Investor RelationsRob Claypoole -...

Accelerated fourth quarter sales growth to 13.5%Fourth quarter gross margin expanded 310 bps and adjusted gross margin* expanded 230 bpsFourth quarter cash from

Bioventus (BVS) delivered earnings and revenue surprises of 66.67% and 5.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Bioventus Inc. (BVS), a medical device company, on Tuesday reported narrower net loss in its fourth quarter with higher revenues. Adjusted earnings and top line beat market estimates.

The stock market on Tuesday, March 11, 2025, shows signs of stabilizing after a tumultuous start to the week. Investors are closely watching major market

Transaction Overview On February 28, 2025, Juniper Investment Company, LLC (Trades, Portfolio) made a strategic decision to reduce its holdings in Lincoln Educa

**media[553373]**

On December 31, 2024, Nantahala Capital Management, LLC (Trades, Portfolio) executed a significant transaction involving Soleno Therapeutics Inc. The firm added

Nantahala Capital Management, LLC (Trades, Portfolio), a prominent investment firm, executed a significant stock transaction on December 31, 2024. The firm adde

Significant Transaction on December 31, 2024 On December 31, 2024, Nantahala Capital Management, LLC (Trades, Portfolio) executed a notable reduction in its hol

Significant Transaction in Surrozen Inc On December 31, 2024, Nantahala Capital Management, LLC (Trades, Portfolio) executed a notable transaction involving Sur

Significant Transaction on December 31, 2024 On December 31, 2024, Nantahala Capital Management, LLC (Trades, Portfolio) executed a notable transaction by incre

Significant Stock Transaction by Nantahala Capital Management, LLC (Trades, Portfolio) On December 31, 2024, Nantahala Capital Management, LLC (Trades, Portfoli

Significant Stock Acquisition by Nantahala Capital Management On December 31, 2024, Nantahala Capital Management, LLC (Trades, Portfolio) executed a notable tra

Transaction Overview On December 31, 2024, Nantahala Capital Management, LLC (Trades, Portfolio) made a significant move by increasing its stake in Altisource P

On December 31, 2024, Nantahala Capital Management, LLC (Trades, Portfolio) made a strategic move by acquiring 3,493,235 shares of Apyx Medical Corp (APYX) at a